| 1. |
- Saha, S., et al.
(author)
-
Observation of rotation about the longest principal axis in Zr 89
- 2019
-
In: Physical Review C. - 2469-9985. ; 99:5
-
Journal article (peer-reviewed)abstract
- High-spin states in Zr89 were populated in the Se80(C13,4n) reaction, and γ-ray coincidences were measured using the Indian National Gamma Array. The level scheme of Zr89 has been extended up to spin I=49/2 with the observation of a new dipole band. Directional correlation and polarization asymmetries of the γ rays have been measured to determine spin and parity of the levels. Line shapes of several transitions have been analyzed to determine lifetimes of the levels. Possible configurations of the band have been discussed using the cranked Nilsson-Strutinsky model. The calculations suggest a triaxial shape of the nucleus at high spins, and the band may represent rotation of the nucleus about the longest axis.
|
|
| 2. |
- Scandariato, G., et al.
(author)
-
CHEOPS (CHaracterizing ExOPlanets Satellite) Mission
- 2016
-
In: Proceedings of Science. - 1824-8039. ; 2016-May
-
Journal article (peer-reviewed)abstract
- The Characterizing ExOPlanet Satellite (CHEOPS) mission was selected in October 2012 by ESA as the first small mission. It will be a ultra-high precision photometer dedicated to the observation of transits of known exoplanets on bright stars, for which the mass has already been measured via ground-based spectroscopic surveys. Its precision will allow the accurate determination of the planetary radii and, by consequence, the planetary bulk density. CHEOPS will also unveil transiting exoplanets of interest for in-depth characterization, a legacy for future instruments suited to the spectroscopic characterization of exoplanetary atmospheres.
|
|
| 3. |
- Gregoire, V, et al.
(author)
-
Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines
- 2018
-
In: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. - : Elsevier BV. - 1879-0887. ; 126:1, s. 3-24
-
Journal article (peer-reviewed)
|
|
| 4. |
- Lacas, Benjamin, et al.
(author)
-
Role of radiotherapy fractionation in head and neck cancers (MARCH) : an updated meta-analysis
- 2017
-
In: The Lancet Oncology. - 1470-2045 .- 1474-5488. ; 18:9, s. 1221-1237
-
Journal article (peer-reviewed)abstract
- Background The Meta-Analysis of Radiotherapy in squamous cell Carcinomas of Head and neck (MARCH) showed that altered fractionation radiotherapy is associated with improved overall and progression-free survival compared with conventional radiotherapy, with hyperfractionated radiotherapy showing the greatest benefit. This update aims to confirm and explain the superiority of hyperfractionated radiotherapy over other altered fractionation radiotherapy regimens and to assess the benefit of altered fractionation within the context of concomitant chemotherapy with the inclusion of new trials. Methods For this updated meta-analysis, we searched bibliography databases, trials registries, and meeting proceedings for published or unpublished randomised trials done between Jan 1, 2009, and July 15, 2015, comparing primary or postoperative conventional fractionation radiotherapy versus altered fractionation radiotherapy (comparison 1) or conventional fractionation radiotherapy plus concomitant chemotherapy versus altered fractionation radiotherapy alone (comparison 2). Eligible trials had to start randomisation on or after Jan 1, 1970, and completed accrual before Dec 31, 2010; had to have been randomised in a way that precluded prior knowledge of treatment assignment; and had to include patients with non-metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx undergoing first-line curative treatment. Trials including a non-conventional radiotherapy control group, investigating hypofractionated radiotherapy, or including mostly nasopharyngeal carcinomas were excluded. Trials were grouped in three types of altered fractionation: hyperfractionated, moderately accelerated, and very accelerated. Individual patient data were collected and combined with a fixed-effects model based on the intention-to-treat principle. The primary endpoint was overall survival. Findings Comparison 1 (conventional fractionation radiotherapy vs altered fractionation radiotherapy) included 33 trials and 11 423 patients. Altered fractionation radiotherapy was associated with a significant benefit on overall survival (hazard ratio [HR] 0·94, 95% CI 0·90–0·98; p=0·0033), with an absolute difference at 5 years of 3·1% (95% CI 1·3–4·9) and at 10 years of 1·2% (−0·8 to 3·2). We found a significant interaction (p=0·051) between type of fractionation and treatment effect, the overall survival benefit being restricted to the hyperfractionated group (HR 0·83, 0·74–0·92), with absolute differences at 5 years of 8·1% (3·4 to 12·8) and at 10 years of 3·9% (−0·6 to 8·4). Comparison 2 (conventional fractionation radiotherapy plus concomitant chemotherapy versus altered fractionation radiotherapy alone) included five trials and 986 patients. Overall survival was significantly worse with altered fractionation radiotherapy compared with concomitant chemoradiotherapy (HR 1·22, 1·05–1·42; p=0·0098), with absolute differences at 5 years of −5·8% (−11·9 to 0·3) and at 10 years of −5·1% (−13·0 to 2·8). Interpretation This update confirms, with more patients and a longer follow-up than the first version of MARCH, that hyperfractionated radiotherapy is, along with concomitant chemoradiotherapy, a standard of care for the treatment of locally advanced head and neck squamous cell cancers. The comparison between hyperfractionated radiotherapy and concomitant chemoradiotherapy remains to be specifically tested. Funding Institut National du Cancer; and Ligue Nationale Contre le Cancer.
|
|
| 5. |
- Laskar, Ruhina S, et al.
(author)
-
Sex specific associations in genome wide association analysis of renal cell carcinoma.
- 2019
-
In: European Journal of Human Genetics. - : Springer Science and Business Media LLC. - 1018-4813 .- 1476-5438. ; 27:10, s. 1589-1598
-
Journal article (peer-reviewed)abstract
- Renal cell carcinoma (RCC) has an undisputed genetic component and a stable 2:1 male to female sex ratio in its incidence across populations, suggesting possible sexual dimorphism in its genetic susceptibility. We conducted the first sex-specific genome-wide association analysis of RCC for men (3227 cases, 4916 controls) and women (1992 cases, 3095 controls) of European ancestry from two RCC genome-wide scans and replicated the top findings using an additional series of men (2261 cases, 5852 controls) and women (1399 cases, 1575 controls) from two independent cohorts of European origin. Our study confirmed sex-specific associations for two known RCC risk loci at 14q24.2 (DPF3) and 2p21(EPAS1). We also identified two additional suggestive male-specific loci at 6q24.3 (SAMD5, male odds ratio (ORmale) = 0.83 [95% CI = 0.78-0.89], Pmale = 1.71 × 10-8 compared with female odds ratio (ORfemale) = 0.98 [95% CI = 0.90-1.07], Pfemale = 0.68) and 12q23.3 (intergenic, ORmale = 0.75 [95% CI = 0.68-0.83], Pmale = 1.59 × 10-8 compared with ORfemale = 0.93 [95% CI = 0.82-1.06], Pfemale = 0.21) that attained genome-wide significance in the joint meta-analysis. Herein, we provide evidence of sex-specific associations in RCC genetic susceptibility and advocate the necessity of larger genetic and genomic studies to unravel the endogenous causes of sex bias in sexually dimorphic traits and diseases like RCC.
|
|
| 6. |
- Lunnan, Ragnhild, et al.
(author)
-
Hydrogen-poor Superluminous Supernovae from the Pan-STARRS1 Medium Deep Survey
- 2018
-
In: Astrophysical Journal. - : American Astronomical Society. - 0004-637X .- 1538-4357. ; 852:2
-
Journal article (peer-reviewed)abstract
- We present light curves and classification spectra of 17 hydrogen-poor superluminous supernovae (SLSNe) from the Pan-STARRS1 Medium Deep Survey (PS1 MDS). Our sample contains all objects from the PS1. MDS sample with spectroscopic classification that are similar to either of the prototypes SN 2005ap or SN 2007bi, without an explicit limit on luminosity. With a redshift range 0.3 < z < 1.6, PS1. MDS is the first SLSN sample primarily probing the high-redshift population; our multifilter PS1 light curves probe the rest-frame UV emission, and hence the peak of the spectral energy distribution. We measure the temperature evolution and construct bolometric light curves, and find peak luminosities of (0.5-5) x 10(44) erg s(-1) and lower limits on the total radiated energies of (0.3-2) x 10(51) erg. The light curve shapes are diverse, with both rise and decline times spanning a factor of similar to 5 and several examples of double-peaked light curves. When correcting for the flux-limited nature of our survey, we find a median peak luminosity at 4000 angstrom of M-4000 = -21.1 mag and a spread of sigma = 0.7 mag.
|
|
| 7. |
|
|
